How should dentists interpret FDA Approves Landmark UW Study: Rapamycin for Periodontal Disease in Older Adults without overstating the findings?

DentalReach Clinical Contributor:

Shared decision-making should present realistic benefits, uncertainties, alternatives, maintenance needs and the consequence of no treatment. This is especially important when the evidence is early or the intervention is irreversible.

DentalReach Evidence Review:

U.S. Food and Drug Administration greenlights Dr. Jonathan An's revolutionary research In a groundbreaking development, the FDA has granted approval to. Interpretation should account for design, sample, comparator, confounding, effect size and follow-up. Statistical association or technical accuracy does not automatically equal a clinically meaningful benefit.

DentalReach Academic Editor:

Stage, grade, inflammatory burden, phenotype, smoking, glycaemic status and maintenance adherence affect applicability. Adjuncts should never displace effective biofilm control, risk modification and supportive periodontal care.